News

DLT evaluation of the monotherapy cohort for GAIA-102 in the clinical trial for pediatric patients with relapsed/refractory solid malignancies has been completed

Research results related to the cultivation technology of GAIA-102 received the Excellent Presentation Award at the 23rd Congress of the Japanese Society for Regenerative Medicine

The clinical trial “GAIA-102 Intraperitoneal Administration in Patients with Advanced Gastrointestinal Cancer of Microsatellite Stable with Malignant Ascites” has been adopted by AMED as part of ’Research Project for Practical Applications of Regenerative Medicine’.

At the 96th Annual Meeting of Japanese Gastric Cancer Association, an interim report on the Phase Ⅰ/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer will be presented.

At the 9th Annual Innate Killer Summit (IKS2024), Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors will be presented.

At the 38th Annual Meeting of Society of Immunotherapy of Cancer (SITC2023), Interim Report of Phase I Clinical Trial of Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102

At the 38th Society for Immunotherapy of Cancer (SITC 2023), an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

At the Asian Oncology Society 2023 (AOS 2023), an interim report on the Phase I/II trial of GAIA-102 for patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites was presented.

At the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

Cellab Healthcare Service (Cellab HS) and GAIA BioMedicine (GAIA) jointly held a press conference to announce that the two firms had executed a business agreement concerning the production of GAIA-102.